First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors

Trial ID # NCT02988817
Phase I/II
Drug Class Antibody Drug Conjugates: Axl
Drug Name Enapotamab vedotin
Alternate Drug Names anti-AXL/MMAE antibody-drug conjugate, anti-AXL monoclonal antibody-MMAE conjugate, HuMax-AXL-ADC
Drugs in Trial Enapotamab vedotin
Eligible Participant

Advanced solid tumors

Patients Enrolled

47 [22 ovarian; median 4 prior therapies (1-9)]

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, RP2D, evaluated per RECIST


RP2D: 2.2 mg/kg 1Q3W

Treatment arm 1Q3W:
ORR: 13% (2PR, n=15)

Clinically Significant Adverse Events

Serious AE: overall (49%)
Grade 3-4 AE: overall (53%), gastrointestinal disorders (constipation, vomiting, diarrhea) (34%), neutropenia (11%)


Manageable safety profile and encouraging anti-tumor activity in heavily pretreated patients


Ameratunga M et al. First in human, dose-escalation, phase (ph) I trial, to evaluate safety of anti-Axl antibody-drug-conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors. J Clin Oncol 37 (2019) (suppl; abstr 2525)

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.